Sana Biotechnology financials
$2.91−0.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$65.4M | -$48.6M | -$61.2M | -$43.5M | -$95.0M | -$50.6M | -$50.9M | -$61.8M | -$49.4M | -$110.7M | -$90.6M | -$2.2M |
| Net income | -$63.6M | -$47.2M | -$58.8M | -$42.2M | -$93.8M | -$49.4M | -$49.1M | -$59.9M | -$50.3M | -$107.5M | -$88.1M | $984.0K |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.22 | $-0.17 | $-0.21 | $-0.16 | $-0.39 | $-0.21 | $-0.21 | $-0.25 | $-0.21 | $-0.49 | $-0.45 | $0.00 |
| EBITDA | -$63.2M | -$46.2M | -$58.1M | -$40.3M | -$47.5M | -$47.0M | -$45.2M | -$57.7M | -$45.5M | -$107.0M | -$90.6M | $2.3M |
| Operating cash flow | -$32.8M | -$37.4M | -$32.6M | -$29.4M | -$33.1M | -$48.7M | -$47.2M | -$51.8M | -$58.5M | -$65.6M | -$52.0M | -$63.5M |
| Free cash flow | -$34.4M | -$37.7M | -$33.5M | -$29.5M | -$33.2M | -$48.8M | -$47.6M | -$55.9M | -$71.6M | -$81.5M | -$66.0M | -$65.8M |
| Diluted shares | 295.7M | 276.9M | 276.5M | 260.5M | 238.4M | 237.6M | 236.4M | 235.4M | 234.4M | 217.3M | 193.9M | 200.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $57.1M | $83.8M | $71.9M | $103.4M | $71.3M | $96.1M |
| Short-term investments | $103.4M | $17.3M | $66.5M | $49.7M | $1.4M | $8.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $431.5M | $373.6M | $416.9M | $435.4M | $361.6M | $445.5M |
| Total liabilities | $277.0M | $254.4M | $256.0M | $240.1M | $239.1M | $236.4M |
| Shareholders' equity | $154.6M | $119.2M | $160.9M | $195.3M | $122.6M | $209.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology